Loading paragraph...
Today's Biggest Stock Losers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| AHMA | Ambitions Enterprise Management L.l.c | $2.24 | -$2.31 | -50.71% | 36.9M | $134M | $1.08$39.50 |
| VALN | Valneva Se | $6.49 | -$3.83 | -37.11% | 759.8K | $888M | $5.43$12.25 |
| AREB | American Rebel | $6.46 | -$2.75 | -29.86% | 74.9K | $69M | $6.20$835,600.00 |
| SWMR | Swarmer | $26.36 | -$10.35 | -28.19% | 4.8M | $453M | $5.00$65.04 |
| WSHP | WeShop | $8.50 | -$3.17 | -27.16% | 997.2K | $274M | $7.11$250.00 |
| ANNA | AleAnna | $5.46 | -$1.62 | -22.84% | 7.9M | $287M | $2.31$18.30 |
| ACXP | Acurx Pharmaceuticals | $4.53 | -$1.08 | -19.20% | 716.4K | $16M | $1.33$21.00 |
| ATLN | Atlantic International | $3.67 | -$0.78 | -17.53% | 4.5K | $279M | $1.16$6.10 |
| ARBB | Arb Iot Group | $4.41 | -$0.76 | -14.62% | 12.2K | $9.1M | $3.92$16.35 |
| ROMA | Roma Green Finance | $5.93 | -$1.01 | -14.55% | 397.2K | $413M | $0.72$8.88 |
| PLTZ | Tidal Trust II - Defiance Daily Target 2x Short Pltr ETF | $24.95 | -$3.83 | -13.31% | 2.1M | - | $19.91$75.28 |
| NERV | Minerva Neurosciences | $6.55 | -$0.99 | -13.13% | 681.2K | $326M | $1.15$12.46 |
| RGTZ | Tidal Trust II - Defiance Daily Target 2x Short Rgti ETF | $22.69 | -$3.34 | -12.83% | 1.6M | - | $8.14$37.48 |
| MGN | Megan | $4.10 | -$0.60 | -12.77% | 1.1M | $76M | $1.00$8.63 |
| KPTI | Karyopharm Therapeutics | $6.66 | -$0.97 | -12.71% | 964.8K | $140M | $3.51$10.99 |
| SBDS | Solo Brands | $3.53 | -$0.51 | -12.62% | 75.6K | $6.7M | $0.54$23.20 |
| ZSTK | ZeroStack | $8.59 | -$1.05 | -10.89% | 33.5K | $23M | $5.86$47.00 |
Related Articles
Featured Article
Thinking About Buying Swarmer After Its Explosive IPO? Here Are 3 Things Investors Need to Know.
Jack Delaney|Mar 21, 2026
Don't let the fear of missing out drive your investing decision.
Is This New Data on Valneva's Less-Effective Booster Concerning?
Keith Speights and Brian Orelli, PhD|Dec 18, 2021
Some recent dismal results for Valneva's vaccine looked bad. But there could be more to the story.
2 Stocks That Could Soar With the Emergence of the Omicron Variant
Keith Speights and Brian Orelli, PhD|Dec 12, 2021
It's too soon to know what the full impact of omicron will be. But these vaccine makers could be particular winners.
These 2 Nasdaq Biotechs Are Making Huge Premarket Moves Monday
Dan Caplinger|Oct 18, 2021
The Nasdaq looks poised to open slightly lower after a strong week.
Should You Buy Stock Now in This New Coronavirus Drug Developer?
David Haen|Apr 29, 2020
This company's repurposed cancer drug might help patients with severe COVID-19.
Your 2 Top Profit Opportunities in 2020
Amar Khatri|Apr 23, 2020
These two underrated biotech stocks have the potential to soar.
Here's Why Karyopharm Therapeutics Has a Unique Growth Opportunity
Amar Khatri|Feb 26, 2020
This cancer-drug maker has a novel medicine with the possibility for extraordinary growth.
Biotech's Most Volatile Binary Events for Q1
David Haen|Jan 3, 2020
Risk-taking investors flock to biotech for its constant flow of events that can spike or crush the stock prices of the companies developing the latest therapies.
Will Karyopharm’s Stock Take Off in 2020?
David Haen|Dec 20, 2019
Early next year, Karyopharm expects to unveil pivotal clinical trial results that could send shares soaring.
These 2 Neuroscience Stocks Have Tanked as Much as 33% Since September 1. Are They Buys?
Maxx Chatsko|Oct 5, 2019
Two healthcare stocks, two plunging stock prices, and two unique scenarios heading into the end of 2019.
